Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chongqing Jianqiao Sues HolleyPharm Again For Patent Infringement

This article was originally published in PharmAsia News

Executive Summary

Chongqing Jianqiao Pharmaceutical Development has again sued Holley Pharmaceuticals, alleging that the latter's Duo-Cotecxin (dihyhroartermisinin piperaquine) tablets infringe on its patented compound for piperaquine tablets. Chongqing Jianqiao demands that HolleyPharm stop production and sale of the product, pay RMB 1 for economic losses, as well as issue a public apology and pay for court expenses. HolleyPharm claims thatDuo-Cotecxin's components are totally different from those of Chongqing Jianqiao's piperaquine tablets and it will be fighting the suit. Meanwhile, HolleyPharm has appealed its previous patent infringement case (PharmAsia News, Jul. 28, 2008). Analysts observe that an unfavourable ruling will negatively impact the firm as it will have to stop producing and selling Duo-Cotecxin locally if it loses the two cases. (Click here for more - Chinese Language)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC067171

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel